Overview of Enrollment/Initiate Period 1 Visit Procedures

What should occur between the Screening and Enrollment visits?

- Review lab results
 - Chemistries (AST/ALT and Creatinine)
 - CBC with differential and platelets
 - Syphilis RPR
 - HSV 1/2 antibody
 - HBsAg
 HBsAb
 Results will indicate if Hep B Vaccine should be offered at Enrollment
 - Hepatitis C antibody
 - Rectal GC/CT

What should occur between the Screening and Enrollment visits?

 Confirm/update Screening column on MTN-017 Eligibility Checklist

ELIGIBILITY CRITERIA	Screening Visit	Enrollment Visit	
Exclusion Criteria	Yes No Staff Initial and Date	l Yes No	
±*1 Participant-reported symptoms, and/or clinical or laboratory diagnosis of active anorectal or reproductive tract infection requiring treatment per current WHO guidelines or symptomatic urinary tract infection (UTI) Source: Baseline Medical History Questions, Pre-existing Conditions CRF, Anorectal Exam CRF, Lab results report			
2 History of inflammatory bowel disease Source: item 4 in Screening Behavioral Eligibity CRF, Baseline Medical History Questions, Pre-existing Conditions CRF		not required	
3a Positive for hepatitis B surface antigen Source: Lab results report		not required	
3b Positive for hepatitis C antibody Source: Lab results report		not required	
3c Hemoglobin < 10.0 g/dL Source: Lab results report		not required	
3d Platelet count less than 100,000/mm3v Source: Lab results report		not required	
3e White blood cell count < 2,000 cells/mm3 or > 15,000 cells/mm3 Source: Lab results report		not required	
3f Calculated creatinine clearance less than 60 mL/min by the Cockcroft-Gault formula [(140-Age) * Mass (in kg)] \ [72 * Serum creatinine (in mg/dL)] Source: Creatinine Clearance calculation worksheet		not required	
3g Serum creatinine > 1.3 x the site laboratory upper limit of normal (ULN) Source: Lab results report		not required	

What <u>administrative</u> procedures should occur <u>before</u> the participant is randomized?

- Confirm participant is within 30-day screening window
- Review/update locator information
- Provide test results from Screening
- Review informed consent and participants' willingness to continue

What <u>behavioral</u> procedures should occur <u>before</u> the participant is randomized?

- Enrollment Behavioral Eligibility (non-DataFax) Case Report Form
- Self Administered CASI Baseline Behavioral Questionnaire

What <u>clinical</u> procedures should occur <u>before</u> the participant is randomized?

- Review/update baseline medical/medication history
- Review/update concomitant medications
- Physical exam
- Rectal exam
- Document Pre-existing conditions
- Provide available test results
- Treatment or referral (if indicated)

What <u>counseling</u> procedures should occur <u>before</u> the participant is randomized?

- HIV pre- & post-test
- HIV/STI risk reduction
- Provision of condoms

What <u>laboratory</u> procedures should occur <u>before</u> the participant is randomized?

- HIV-1 serology
- Plasma archive

Note: Sites not conducting HIV rapids via finger stick, can collect plasma archive and HIV samples as part of a single blood draw in order to reduce participant burden.

What other procedure should occur <u>before</u> the participant is randomized?

- Conduct final determination of eligibility status
 - Review/complete Enrollment Visit column on Eligibility checklist

ELIGIBILITY CRITERIA	Screening Visit			Enrollment Visit	
Inclusion Criteria	Yes	No	Staff Initials and Date	Yes No	Staff Initials and Date
 Male or transgender female ≥ age of 18 at Screening 				not required	
2. Able and willing to provide written informed consent				not required	
3. HIV-1 uninfected					7
4. Able and willing to provide adequate locator information					
5. Available to return for all study visits and willing to comply with study participation requirements					
6. In general good health					
7. History of consensual RAI at least once in the past 3 months				not required	

Is study approved lubricant provided at all study visits?

1. No

2. Yes

When is study lubricant required to be provided?

What procedures should occur <u>after</u> the participant is randomized?

- Provide relevant product use instructions and lubricant, if indicated
- Observe participant first dose/simulation of first does
 - Daily tablet the first dose should be directly observed by study staff.
 - <u>Daily rectal gel</u> first insertion or simulation of first insertion should be performed in a private space
 - RAI rectal gel simulation of first insertion should be done in a private space
- Provide protocol adherence counseling

What other <u>counseling</u> procedure should occur <u>after</u> the participant is randomized?

 Provide participant-centered product adherence counseling

Note: Should not be the same staff person who provided product use instruction and protocol adherence counseling

What procedures should occur <u>after</u> the participant is randomized?

- Provide relevant SMS training and SMS diary instructions
- Generate and provide follow-up visit schedule
- Provide reimbursement
- Remind participant of follow-up phone calls:
 - 48-72 hours from date of expected product initiation
 - 2 weeks from date of expected product initiation

Questions?